IM1240 tri-specific antibody (capped-CD3x5T4xNKG2A): Investigational New Drug (IND) application submission planned during 2027, followed by a first-in-human study IM1240 data to be presented in a plenary oral session at the 38th EORTC-NCI-AACR Symposium on November 20, 2026 REHOVOT, Israel, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize
Detailed price information for Purple Biotech Ltd ADR (PPBT-Q) from The Globe and Mail including charting and trades.
Purple Biotech (NASDAQ:PPBT) has received a U. S.
Purple Biotech (PPBT) said Wednesday that the US Patent and Trademark Office has issued a "Notice of
Achieved commercially viable yield for IM1240, positioning the program competitively for future development Validates scalability of the CAPTN-3...
Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific...
This is the newest page. Registered accounts read further back.